Curis Pipeline

Curis is focused on the development and commercialization of innovative therapeutics for the treatment of cancer.

  • Fimepinostat (formerly known as CUDC-907) is an orally-available, small molecule inhibitor of histone deacetylase, or HDAC, and phosphatidylinositol-3-kinase, or PI3K enzymes. Curis is currently investigating fimepinostat in two studies: a Phase 2 clinical trial in patients with relapsed, refractory diffuse large B-cell lymphoma, or DLBCL, and a Phase 1 trial in patients with solid tumors.
  • CA-170 is a first-in-class, orally-available, small molecule antagonist of the immune checkpoints VISTA and PD-L1. CA-170 is currently undergoing investigation in a Phase 1 clinical trial in patients with advanced solid tumors and lymphoma.
  • CA-4948 is an orally-available, small molecule inhibitor of the IRAK4 kinase and is currently being tested in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma.
  • CA-327 is a first-in-class, orally-available, small molecule antagonist of the immune checkpoints TIM3 and PD-L1.
  • Erivedge® (vismodegib) was developed in collaboration with Genentech (a member of the Roche group) and is being commercialized by Genentech and Roche for the treatment of advanced basal cell carcinoma (BCC). Erivedge® is approved for use in patients with advanced BCC in the United States, European Union, and several other countries.